🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This comes after revelations that a much-touted deal on medicines, which commits to zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond broad headline terms outlined by government press releases.

A Deal Without Detail

The deal on drug tariffs, described as a "landmark" achievement, exists as an "broad understanding" without a signed legal text. Observers point out that the press releases from the UK and US governments describe the deal in sharply different terms. The British version emphasizes securing "zero per cent tariffs" as a singular success, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for nothing more than a verbal promise from President Trump," commented David Henig, a trade policy analyst. "History shows he has a tendency for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been intensified by Washington's move to pause the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an earlier tariff deal have still not been formally ratified by the US, despite a fast-approaching January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Privately, ministers have voiced worries that the government's agreements with the US are lacking substance. One minister reportedly said the series of agreements as "built on sand," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, argued: "Perhaps most shocking than the administration's tactics is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Officials have downplayed the chances of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that instability is inherent in dealing with the current US leadership. However, they maintain that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

However, delays have emerged in enacting the May tariff agreement. Promised access for British beef have yet to be finalized, and the assurance to "reduce steel tariffs to zero" has is still pending, with tariffs fixed at 25%.

Looking ahead, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.